Efficacy and safety of donepezil in patients with dementia with Lewy bodies: results from a 12‐week multicentre, randomised, double‐blind, and placebo‐controlled phase IV study

Abstract

AbstractBackgroundDonepezil has been approved in Japan for the treatment of dementia with Lewy bodies (DLB) based on clinical trials showing its beneficial effects on cognitive impairment. This phase IV study evaluated the efficacy of donepezil by focusing on global clinical status during a 12‐week double‐blind phase.MethodsPatients with probable DLB were randomly assigned to the placebo (n = 79) or 10 mg donepezil (n = 81) groups. The primary endpoint was changes in global clinical status, assessed using the Clinician's Interview‐Based Impression of Change plus Caregiver Input (CIBIC‐plus). We also assessed four CIBIC‐plus domains (general condition, cognitive function, behaviour, and activities of daily living) and changes in cognitive impairment and behavioural and neuropsychiatric symptoms measured using the Mini‐Mental State Examination (MMSE) and the Neuropsychiatric Inventory (NPI), respectively.ResultsAlthough donepezil's superiority was not shown in the global clinical status, a significant favourable effect was detected in the cognitive domain (P = 0.006). MMSE scores improved in the donepezil group after adjustments in post hoc analysis (MMSE mean difference, 1.4 (95% confidence interval (CI), 0.42–2.30), P = 0.004). Improvements in NPIs were similar between the groups (NPI‐2: −0.2 (95% CI, −1.48 to 1.01), P = 0.710; NPI‐10: 0.1 (95% CI, −3.28 to 3.55), P = 0.937).ConclusionThe results support the observation that the efficacy of 10 mg donepezil in improving cognitive function is clinically meaningful in DLB patients. The evaluation of global clinical status might be affected by mild to moderate DLB patients enrolled in this study. No new safety concerns were detected.